StockData

IRulya Therapeutics Inc. (IRLA) stock

IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 5/30
$40.59+2.14 (+5.57%)

Close on Nov 18, 2026Market cap $41.28MP/E –Yield –

IRulya Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

IRulya Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$127.16M. For fiscal 2025 it was -$58.07M. The highest annual figure on record is -$12.12M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$58.07M–
FY2024Dec 31, 2024-$57.29M–
FY2023Dec 31, 2023-$34.62M–
FY2022Dec 31, 2022-$52.02M–
FY2021Dec 31, 2021-$90.32M–
FY2020Dec 31, 2020-$78.89M–
FY2019Dec 31, 2019-$39.17M–
FY2018Dec 31, 2018-$12.12M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$79.78M–
Q1 FY2026Mar 31, 2026-$14.59M–
Q4 FY2025Dec 31, 2025-$19.35M–
Q3 FY2025Sep 30, 2025-$13.43M–
Q2 FY2025Jun 30, 2025-$10.43M–
Q1 FY2025Mar 31, 2025-$14.86M–
Q4 FY2024Dec 31, 2024-$12.01M–
Q3 FY2024Sep 30, 2024-$5.86M–
Q2 FY2024Jun 30, 2024-$28.19M–
Q1 FY2024Mar 31, 2024-$11.22M–
Q4 FY2023Dec 31, 2023-$9.92M–
Q3 FY2023Sep 30, 2023-$6.09M–
Q2 FY2023Jun 30, 2023-$5.58M–
Q1 FY2023Mar 31, 2023-$12.96M–
Q4 FY2022Dec 31, 2022-$6.32M–
Q3 FY2022Sep 30, 2022-$7.62M–
Q2 FY2022Jun 30, 2022-$16.26M–
Q1 FY2022Mar 31, 2022-$21.86M–
Q4 FY2021Dec 31, 2021-$23.54M–
Q3 FY2021Sep 30, 2021-$21.68M–
Q2 FY2021Jun 30, 2021-$21.78M–
Q1 FY2021Mar 31, 2021-$23.31M–
Q4 FY2020Dec 31, 2020-$20.85M–
Q3 FY2020Sep 30, 2020-$21.91M–
Q2 FY2020Jun 30, 2020-$18.27M–
Q1 FY2020Mar 31, 2020-$17.86M–
Q4 FY2019Dec 31, 2019-$12.95M–
Q3 FY2019Sep 30, 2019-$10.57M–
Q2 FY2019Jun 30, 2019-$9.58M–
Q1 FY2019Mar 31, 2019-$6.08M–
Q4 FY2018Dec 31, 2018-$3.84M–
Q3 FY2018Sep 30, 2018-$2.87M–
Q2 FY2018Jun 30, 2018-$2.64M–
Q1 FY2018Mar 31, 2018-$2.76M–

More IRulya Therapeutics figures

See a number that looks wrong?